Afatinib. Afatinib is an inhibitor for EGFR and ERBBs (HER2, HER4) and was approved by the FDA for metastatic NSCLC with non-resistant EGFR mutations (EGFR S768I, L861Q, and G719X) [149]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.